AMERICAN ACADEMY of PEDIATRICS the Transfer of Drugs

Total Page:16

File Type:pdf, Size:1020Kb

AMERICAN ACADEMY of PEDIATRICS the Transfer of Drugs AMERICAN ACADEMY OF PEDIATRICS Committee on Drugs The Transfer of Drugs and Other Chemicals Into Human Milk ABSTRACT. The American Academy of Pediatrics exposure. Nicotine is not necessarily the only com- places emphasis on increasing breastfeeding in the ponent that might cause an increase in respiratory United States. A common reason for the cessation of illnesses (including otitis media) in the nursing in- breastfeeding is the use of medication by the nursing fant attributable to both transmammary secretion of mother and advice by her physician to stop nursing. Such compounds and environmental exposure. Nicotine is advice may not be warranted. This statement is intended to supply the pediatrician, obstetrician, and family phy- present in milk in concentrations between 1.5 and 3.0 sician with data, if known, concerning the excretion of times the simultaneous maternal plasma concentra- 15 drugs into human milk. Most drugs likely to be pre- tion, and elimination half-life is similar—60 to 90 scribed to the nursing mother should have no effect on minutes in milk and plasma.7 There is no evidence to milk supply or on infant well-being. This information is document whether this amount of nicotine presents a important not only to protect nursing infants from unto- health risk to the nursing infant. ward effects of maternal medication but also to allow The Committee on Drugs wishes to support the effective pharmacologic treatment of breastfeeding emphasis of the American Academy of Pediatrics on mothers. Nicotine, psychotropic drugs, and silicone im- increasing breastfeeding in the United States. Preg- plants are 3 important topics reviewed in this statement. nancy and lactation are ideal occasions for physi- INTRODUCTION cians to urge cessation of smoking. It is recognized that there are women who are unable to stop smok- statement on the transfer of drugs and chem- ing cigarettes. One study reported that, among icals into human milk was first published in women who continue to smoke throughout breast- 1983,1 with revisions in 19892 and 1994.3 In- A feeding, the incidence of acute respiratory illness is formation continues to become available. The current decreased among their infants, compared with in- statement is intended to revise the lists of agents fants of smoking mothers who are bottle fed.16 It may transferred into human milk and describe their pos- be that breastfeeding and smoking is less detrimental sible effects on the infant or on lactation, if known (Tables 1–7). If a pharmacologic or chemical agent to the child than bottle feeding and smoking. The does not appear in the tables, it does not mean that it Committee on Drugs awaits more data on this issue. is not transferred into human milk or that it does not The Committee on Drugs therefore has not placed have an effect on the infant; it only indicates that nicotine (and thus smoking) in any of the Tables but there were no reports found in the literature. These hopes that the interest in breastfeeding by a smoking tables should assist the physician in counseling a woman will serve as a point of discussion about nursing mother regarding breastfeeding when the smoking cessation between the pediatrician and the mother has a condition for which a drug is medically prospective lactating woman or nursing mother. Al- indicated. ternate (oral, transcutaneous) sources of nicotine to assist with smoking cessation, however, have not BREASTFEEDING AND SMOKING been studied sufficiently for the Committee on Drugs In the previous edition of this statement, the Com- to make a recommendation for or against them in mittee on Drugs placed nicotine (smoking) in Table breastfeeding women. 2, “Drugs of Abuse-Contraindicated During Breast- feeding.” The reasons for placing nicotine and, thus, PSYCHOTROPIC DRUGS smoking in Table 2 were documented decrease in Anti-anxiety drugs, antidepressants, and neuro- milk production and weight gain in the infant of the leptic drugs have been placed in Table 4, “Drugs for smoking mother and exposure of the infant to envi- Which the Effect on Nursing Infants is Unknown but ronmental tobacco smoke as demonstrated by the May Be of Concern.” These drugs appear in low presence of nicotine and its primary metabolite, co- 4–12 concentrations (usually with a milk-to-plasma ratio tinine, in human milk. There is controversy re- of 0.5–1.0) in milk after maternal ingestion. Because garding the effects of nicotine on infant size at 1 year 13,14 of the long half-life of these compounds and some of of age. There are hundreds of compounds in their metabolites, nursing infants may have measur- tobacco smoke; however, nicotine and its metabolite able amounts in their plasma and tissues, such as the acotinine are most often used as markers of tobacco brain. This is particularly important in infants during the first few months of life, with immature hepatic The recommendations in this statement do not indicate an exclusive course and renal function. Nursing mothers should be in- of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate. formed that if they take one of these drugs, the infant PEDIATRICS (ISSN 0031 4005). Copyright © 2001 by the American Acad- will be exposed to it. Because these drugs affect emy of Pediatrics. neurotransmitter function in the developing central 776 PEDIATRICS Vol.Downloaded 108 No. 3from September www.aappublications.org/news 2001 by guest on September 24, 2021 nervous system, it may not be possible to predict quantitate drugs in milk continue to improve, this long-term neurodevelopmental effects. information will require frequent updating. Drugs cited in Tables 1 through 7 are listed in alphabetical SILICONE BREAST IMPLANTS AND order by generic name; brand names are available BREASTFEEDING from the current Physicians’ Desk Reference,23 USP DI Approximately 800 000 to 1 million women in the 2001: Drug Information for the Health Care Professional, United States have received breast implants contain- Volume I,24 and USP Dictionary of USAN and Interna- ing silicone (elemental silicon with chemical bonds to tional Drug Names.25 The reference list is not inclusive oxygen) in the implant envelope or in the envelope of all articles published on the topic. and the interior gel. Concern has been raised about Physicians who encounter adverse effects in in- the possible effects to the nursing infant if mothers fants who have been receiving drug-contaminated with implants breastfeed. This concern was initially human milk are urged to document these effects in a raised in reports that described esophageal dysfunc- communication to the Food and Drug Administra- tion in 11 children whose mothers had implants.17,18 tion (http://www.fda.gov/medwatch/index.html) This finding has not been confirmed by other reports. and to the Committee on Drugs. This communication Silicone chemistry is extremely complex; the poly- should include the generic and brand names of the mer involved in the covering and the interior of the drug, the maternal dose and mode of administration, breast implant consists of a polymer of alternating the concentration of the drug in milk and maternal silicon and oxygen atoms with methyl groups at- and infant blood in relation to the time of ingestion, tached to the oxygen groups (methyl polydimethyl- the method used for laboratory identification, the siloxane).19 The length of the polymer determines age of the infant, and the adverse effects. Such re- whether it is a solid, gel, or liquid. There are only a ports may substantially increase the pediatric com- few instances of the polymer being assayed in the munity’s fund of knowledge regarding drug transfer milk of women with implants; the concentrations are into human milk and the potential or actual risk to not elevated over control samples.20 There is no ev- the infant. idence at the present time that this polymer is di- rectly toxic to human tissues; however, concern also Committee on Drugs, 2000–2001 exists that toxicity may be mediated through an im- Robert M. Ward, MD, Chairperson munologic mechanism. This has yet to be confirmed Brian A. Bates, MD William E. Benitz, MD in humans. Except for the study cited above, there David J. Burchfield, MD have been no other reports of clinical problems in John C. Ring, MD 21 infants of mothers with silicone breast implants. It Richard P. Walls, MD, PhD is unlikely that elemental silicon causes difficulty, Philip D. Walson, MD because silicon is present in higher concentrations in Liaisons cow milk and formula than in milk of humans with 22 John Alexander, MD implants. The anticolic compound simethicone is a Food and Drug Administration Alternate silicone and has a structure very similar to the Donald R. Bennett, MD, PhD methyl polydimethylsiloxane in breast implants. American Medical Association/United States Simethicone has been used for decades in this coun- Pharmacopeia try and Europe without any evidence of toxicity to Therese Cvetkovich, MD infants. The Committee on Drugs does not feel that Food and Drug Administration the evidence currently justifies classifying silicone Owen R. Hagino, MD implants as a contraindication to breastfeeding. American Academy of Child and Adolescent Psychiatry DRUG THERAPY OF THE LACTATING WOMAN Stuart M. MacLeod, MD, PhD Canadian Paediatric Society The following should be considered before pre- Siddika Mithani, MD scribing drugs to lactating women: Bureau of Pharmaceutical Assessment Health 1. Is drug therapy really necessary? If drugs are Protection Branch, Canada required, consultation between the pediatrician Joseph Mulinare, MD, MSPH Centers for Disease Control and Prevention and the mother’s physician can be most useful in Laura E. Riley, MD determining what options to choose. American College of Obstetricians and 2. The safest drug should be chosen, for example, Gynecologists acetaminophen rather than aspirin for analgesia.
Recommended publications
  • Progestogen-Only Contraceptive Use Among Breastfeeding Women: a System- Atic Review
    ÔØ ÅÒÙ×Ö ÔØ Progestogen-only contraceptive use among breastfeeding women: A system- atic review Sharon J. Phillips, Naomi K. Tepper, Nathalie Kapp, Kavita Nanda, Marleen Temmerman, Kathryn M. Curtis PII: S0010-7824(15)00585-5 DOI: doi: 10.1016/j.contraception.2015.09.010 Reference: CON 8613 To appear in: Contraception Received date: 7 May 2015 Revised date: 20 September 2015 Accepted date: 21 September 2015 Please cite this article as: Phillips Sharon J., Tepper Naomi K., Kapp Nathalie, Nanda Kavita, Temmerman Marleen, Curtis Kathryn M., Progestogen-only contracep- tive use among breastfeeding women: A systematic review, Contraception (2015), doi: 10.1016/j.contraception.2015.09.010 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Progestogen-only contraceptive use among breastfeeding women: A systematic review Sharon J. Phillips1, Naomi K. Tepper2, Nathalie Kapp3, Kavita Nanda4, Marleen Temmerman1, Kathryn M. Curtis2 1Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland (prior affiliation) 2Division of Reproductive Health, US Centers for Disease Control and Prevention, Atlanta, GA, USA 3Independent reproductive health consultant, Paris, France 4FHI 360, Durham, NC, USA The findings and conclusions in this report are those of the authors and do not necessarily represent the officialACCEPTED position of the World MANUSCRIPT Health Organization or US Centers for Disease Control and Prevention.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • AAP the Transfer of Drugs and Chemicals Into Human Milk
    AMERICAN ACADEMY OF PEDIATRICS Committee on Drugs The Transfer of Drugs and Other Chemicals Into Human Milk ABSTRACT. The American Academy of Pediatrics exposure. Nicotine is not necessarily the only com- places emphasis on increasing breastfeeding in the ponent that might cause an increase in respiratory United States. A common reason for the cessation of illnesses (including otitis media) in the nursing in- breastfeeding is the use of medication by the nursing fant attributable to both transmammary secretion of mother and advice by her physician to stop nursing. Such compounds and environmental exposure. Nicotine is advice may not be warranted. This statement is intended to supply the pediatrician, obstetrician, and family phy- present in milk in concentrations between 1.5 and 3.0 sician with data, if known, concerning the excretion of times the simultaneous maternal plasma concentra- 15 drugs into human milk. Most drugs likely to be pre- tion, and elimination half-life is similar—60 to 90 scribed to the nursing mother should have no effect on minutes in milk and plasma.7 There is no evidence to milk supply or on infant well-being. This information is document whether this amount of nicotine presents a important not only to protect nursing infants from unto- health risk to the nursing infant. ward effects of maternal medication but also to allow The Committee on Drugs wishes to support the effective pharmacologic treatment of breastfeeding emphasis of the American Academy of Pediatrics on mothers. Nicotine, psychotropic drugs, and silicone im- increasing breastfeeding in the United States. Preg- plants are 3 important topics reviewed in this statement.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • United States Patent (10) Patent No.: US 7,199,243 B2
    US007 1992.43B2 (12) United States Patent (10) Patent No.: US 7,199,243 B2 Baglev et al. 45) Date of Patent: Apr. 3,9 2007 (54) PIPERIDINE COMPOUNDS USEFUL AS 6,376,494 B1 4/2002 Childers et al. ....... 514, 252.14 PPARACTIVATORS FOREIGN PATENT DOCUMENTS (75) Inventors: Scott W. Bagley, Mystic, CT (US); EP O548798 * 6, 1993 Thomas A. Brandt, North Stonington, JP O2.173426 g2002 CT (US); Robert W. Dugger, WO WO9210468 6, 1992 Stonington, CT (US); William A WO WO9219594 11, 1992 glon, s WO WO9307 141 4f1993 Hada, Waterford, CT (US); Cheryl M. WO WO 93.12086 6, 1993 Hayward, Old Lyme, CT (US); WO WO 96.02250 * 2, 1996 Zhengyu Liu, Carlsbad, CA (US) WO WO9602250 2, 1996 WO WO 9736579 10, 1997 (73) Assignees: Pfizer Inc., New York, NY (US); Pfizer WO WO9805331 2, 1998 Products Inc., Groton, CT (US) WO WO OO14066 3, 2000 WO WOOO234O7 4/2000 (*) Notice: Subject to any disclaimer, the term of this WO WO O1f90101 * 11, 2001 patent is extended or adjusted under 35 W W 93. H3. U.S.C. 154(b) by 340 days. WO WO O190101 11 2001 WO WO O228834 4/2002 (21) Appl. No.: 10/720,942 WO WO O23O896 4/2002 WO WO O2O64139 8, 2002 (22) Filed: Nov. 24, 2003 WO WO O2O64549 8, 2002 (65) Prior Publication Data OTHER PUBLICATIONS Palani et al., Journal of Medicinal Chemistry, 2005, 48, 4746.* US 2004/O157885 A1 Aug. 12, 2004 Heinone, T. Currect Atherosclerosis Reports, 2002, 4(1), Sum O O mary.* Related U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]